The impact of high-risk patients on the results of clinical trials.

The results of clinical trials may not reflect equally the experiences of all their individual participants. By modeling populations where patients have very diverse baseline risks of suffering an event of interest, it can be seen that very sick patients of high risk become the major determinants of how many events occur in the whole population, even though they may represent only a small minority. Human immunodeficiency virus-related trials and trials of magnesium in acute myocardial infarction are analyzed. When the benefit or toxicity from a treatment varies with the baseline risk of each patient, the treatment effect may be markedly different in populations with a different representation of high- and low-risk patients. The results of small clinical trials studying heterogeneous populations with binary outcomes depend on the sampling and outcomes of very few high risk participants. Conversely, mega-trials studying homogeneous populations would miss subgroups or individuals with diverse treatment responses. In both cases, aggregate trial results may be misleading for the care of many individuals.

[1]  Bernard Hirschel,et al.  Concorde trial of immediate versus deferred zidovudine , 1994, The Lancet.

[2]  M A Fischl,et al.  The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. , 1987, The New England journal of medicine.

[3]  R. Kloner,et al.  An experimental model examining the role of magnesium in the therapy of acute myocardial infarction. , 1995, The American journal of cardiology.

[4]  S. Fletcher,et al.  Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2) , 1992, The Lancet.

[5]  R Peto,et al.  Effects of intravenous magnesium in suspected acute myocardial infarction: overview of randomised trials. , 1991, BMJ.

[6]  W. Herzog,et al.  Timing of magnesium therapy affects experimental infarct size. , 1995, Circulation.

[7]  A. Phillips,et al.  Factors affecting survival in patients with the acquired immunodeficiency syndrome. , 1996, AIDS.

[8]  F. Song,et al.  Cholesterol lowering and mortality: the importance of considering initial level of risk. , 1993, BMJ.

[9]  T. Chalmers,et al.  Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration , 1994, The Lancet.

[10]  J. Collet,et al.  An Effect Model for the Assessment of Drug Benefit: Example of Antiarrhythmic Drugs in Postmyocardial Infarction Patients , 1993, Journal of cardiovascular pharmacology.

[11]  J. Singer,et al.  A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. , 1996, The New England journal of medicine.

[12]  L. La Voie,et al.  Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A double-blind, placebo-controlled trial. , 1990, The New England journal of medicine.

[13]  J W Mulder,et al.  Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group. , 1996, The Journal of infectious diseases.

[14]  R. Baughman,et al.  Trimetrexate with leucovorin versus trimethoprim-sulfamethoxazole for moderate to severe episodes of Pneumocystis carinii pneumonia in patients with AIDS: a prospective, controlled multicenter investigation of the AIDS Clinical Trials Group Protocol 029/031. , 1994, The Journal of infectious diseases.

[15]  Ann Collier,et al.  Combination and Monotherapy with Zidovudine and Zalcitabine in Patients with Advanced HIV Disease , 1995, Annals of Internal Medicine.

[16]  R. Califf,et al.  Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO trial , 1997, The Lancet.

[17]  S. Hammer,et al.  A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. , 1996, The New England journal of medicine.

[18]  J. Falloon,et al.  Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. , 1993, The New England journal of medicine.

[19]  M. Jacobson,et al.  A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS. , 1993, The Journal of infectious diseases.

[20]  C. Rizza,et al.  Importance of age at infection with HIV-1 for survival and development of AIDS in UK haemophilia population , 1996, The Lancet.

[21]  J. Ioannidis,et al.  Predictive value of viral load measurements in asymptomatic untreated HIV‐1 infection: a mathematical model , 1996, AIDS.

[22]  A. Mocroft,et al.  Staging system for clinical AIDS patients , 1995, The Lancet.

[23]  F. Raffi,et al.  Lower survival in AIDS patients receiving dapsone compared with aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia. Study Group. , 1995, The Journal of infectious diseases.

[24]  M A Fischl,et al.  The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. , 1987, The New England journal of medicine.

[25]  George Davey Smith,et al.  Misleading meta-analysis , 1995, BMJ.

[26]  M. Moroni,et al.  The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS‐related complex: a double‐blind, randomized trial , 1993 .

[27]  T C Chalmers,et al.  Cumulative meta-analysis of therapeutic trials for myocardial infarction. , 1992, The New England journal of medicine.

[28]  R. Chaisson,et al.  Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic: Mycobacterium avium complex disease in patients with HIV infection , 1997, AIDS.

[29]  G. Rutherford,et al.  Survival trends for patients with AIDS. , 1990, JAMA.

[30]  A. LaMarca,et al.  A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. , 1996, The New England journal of medicine.

[31]  J Col,et al.  Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. , 1995, Circulation.

[32]  Raymond C. Schneider,et al.  ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction , 1995, The Lancet.

[33]  John W. Mellors,et al.  Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.

[34]  J. Touraine,et al.  Beneficial effects of intravenous immunoglobulins in AIDS , 1992, The Lancet.

[35]  D. Ho,et al.  Viral Counts Count in HIV Infection , 1996, Science.

[36]  L. Goldman,et al.  The recent decline in mortality from coronary heart disease, 1980-1990. The effect of secular trends in risk factors and treatment. , 1997, JAMA.

[37]  J. Ioannidis,et al.  Large trials vs meta-analysis of smaller trials. How do their results compare? , 1997 .

[38]  K. Bailey,et al.  Generalizing the results of randomized clinical trials. , 1994, Controlled clinical trials.

[39]  Ann Marie Swart,et al.  Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection , 1994, The Lancet.

[40]  J. Mellors,et al.  Quantitation of HIV-1 RNA in Plasma Predicts Outcome after Seroconversion , 1995, Annals of Internal Medicine.

[41]  B. Gazzard,et al.  Effects of high‐dose oral acyclovir on herpesvirus disease and survival in patients with advanced HIV disease: a double‐blind, placebo‐controlled study , 1994 .

[42]  P. Rothwell,et al.  Can overall results of clinical trials be applied to all patients? , 1995, The Lancet.

[43]  D. Richman,et al.  A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. , 1990, The New England journal of medicine.

[44]  C. Sabin,et al.  Immunodeficiency and the risk of death in HIV infection. , 1992, JAMA.

[45]  J P Matts,et al.  Primary prophylaxis with pyrimethamine for toxoplasmic encephalitis in patients with advanced human immunodeficiency virus disease: results of a randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS. , 1994, The Journal of infectious diseases.

[46]  J. Ioannidis,et al.  Impact of epidemic and individual heterogeneity on the population distribution of disease progression rates. An example from patient populations in trials of human immunodeficiency virus infection. , 1996, American journal of epidemiology.

[47]  E. Antman.  Randomized trials of magnesium in acute myocardial infarction: big numbers do not tell the whole story. , 1995, The American journal of cardiology.

[48]  Les M Irwig,et al.  An evidence based approach to individualising treatment , 1995, BMJ.

[49]  J. Bartlett,et al.  Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis , 1991 .

[50]  J. Darbyshire,et al.  Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals , 1996, The Lancet.

[51]  S G Thompson,et al.  Controversies in meta-analysis: the case of the trials of serum cholesterol reduction , 1993, Statistical methods in medical research.

[52]  M. McIntosh,et al.  The population risk as an explanatory variable in research synthesis of clinical trials. , 1996, Statistics in medicine.

[53]  C. Christensen,et al.  Magnesium sulfate reduces myocardial infarct size when administered before but not after coronary reperfusion in a canine model. , 1995, Circulation.

[54]  G. Baxter,et al.  Infarct size and magnesium: insights into LIMIT-2 and ISIS-4 from experimental studies , 1996, The Lancet.

[55]  R. Collins,et al.  ISIS-4 - REPLY , 1995 .

[56]  J. Tuomilehto,et al.  21 year trends in incidence of myocardial infarction and mortality from coronary disease in middle-age. , 1996, European heart journal.

[57]  K. Woods.  Mega-trials and management of acute myocardial infarction , 1995, The Lancet.

[58]  J. Goedert,et al.  Influence of combinations of human major histocompatibility complex genes on the course of HIV–1 infection , 1996, Nature Medicine.

[59]  D. Rubin.  Meta-Analysis: Literature Synthesis or Effect-Size Surface Estimation? , 1992 .

[60]  H. Sacks,et al.  Early or Deferred Zidovudine Therapy in HIV-Infected Patients without an AIDS-Defining Illness , 1995, Annals of Internal Medicine.

[61]  J J Goedert,et al.  Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene , 1996, Science.